1.Clinical meaning of sarcopenia in patients undergoing endoscopic treatment
Hiroyuki HISADA ; Yosuke TSUJI ; Hikaru KURIBARA ; Ryohei MIYATA ; Kaori OSHIO ; Satoru MIZUTANI ; Hideki NAKAGAWA ; Rina CHO ; Nobuyuki SAKUMA ; Yuko MIURA ; Hiroya MIZUTANI ; Daisuke OHKI ; Seiichi YAKABI ; Yu TAKAHASHI ; Yoshiki SAKAGUCHI ; Naomi KAKUSHIMA ; Nobutake YAMAMICHI ; Mitsuhiro FUJISHIRO
Clinical Endoscopy 2024;57(4):446-453
With increasing global life expectancy, the significance of geriatric assessment parameters has increased. Sarcopenia is a crucial assessment parameter and is defined as the age-related loss of muscle mass and strength. Sarcopenia is widely acknowledged as a risk factor for postoperative complications in diverse advanced malignancies and has a detrimental effect on the long-term prognosis. While most studies have primarily concentrated on the correlation between sarcopenia and advanced cancer, more recent investigations have focused on the relationship between sarcopenia and early-stage cancer. Endoscopic submucosal dissection (ESD), which is less invasive than surgical intervention, is extensively employed in the management of early-stage cancer, although it is associated with complications such as bleeding and perforation. In recent years, several reports have revealed the adverse consequences of sarcopenia in patients with early-stage cancer undergoing ESD. This literature review briefly summarizes the recent studies on the association between sarcopenia and ESD.